Jemperli (dostarlimab) [product information]. EMA.

Regulatory approval published by the European Medicines Agency.

Citation

GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised January 2024. Accessed March 9, 2024.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. 2
JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen. 2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) dMMR Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (+) MSI-H Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (+) dMMR Endometrial Carcinoma Dostarlimab
Sensitivity (+) MSI-H Endometrial Carcinoma Dostarlimab